FIT BIOTECH OY
Company announcement
September 5, 2016 at 15:30 EET
FIT Biotech to repeat it’s proof-of-concept gene-based treatment study
FIT Biotech plans to repeat it’s pivotal proof-of-concept study in gene-based treatment due to an unexpected malfunction of the electroporation device (EP). The EP device is used to enhance uptake of DNA-plasmid into targeted cells. The study will be repeated with a new EP device and it is expected to be completed and reported in Q1/2017.
FIT Biotech’s other projects as listed in the May 20, 2016, and the June 10, 2016, company releases are progressing according to the operational plan.
FIT BIOTECH OY
Further information:
James Kuo
CEO, FIT Biotech Oy
Tel: +358 3 3138 7000
E-mail: james.kuo@fitbiotech.com
Certified Advisor: Translink Corporate Finance Oy, tel. +358 20 743 2790
FIT Biotech in brief
FIT Biotech Oy is a biotechnology company established in 1995 that develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies GTU® technology in its drug development programs. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.
FIT Biotech shares are listed on the First North Finland market maintained by Nasdaq Helsinki Oy.
DISTRIBUTION:
Nasdaq Helsinki
Principal media
www.fitbiotech.com
